Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.35 |
| ▸ | PRKG1 | Q13976 | 4/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26925456 | 0.85 | PDE1C (0.43) | PDE1CHDAC4PTGER3ROCK2PRKG1 | |
| SCHEMBL30731861 | 0.80 | DDB1 (0.38) | GPR119PDE4BROCK2PRKG1 | |
| SCHEMBL24338720 | 0.80 | GLP1R (0.40) | GPR119 | |
| SCHEMBL30174476 | 0.80 | GLP1R (0.40) | GPR119 | |
| SCHEMBL21382045 | 0.80 | SCD5 (0.47) | PDE1CGPR119HDAC4PDE4BFASN | |
| SCHEMBL30120502 | 0.80 | SCD5 (0.47) | PDE1CGPR119HDAC4PDE4BFASN | |
| SCHEMBL7151596 | 0.79 | KDM4E (0.44) | PDE4BROCK2PRKG1 | |
| SCHEMBL2158777 | 0.76 | MEN1 (0.43) | GPR119 | |
| SCHEMBL23868538 | 0.76 | ROCK2 (0.50) | GPR119PDE4BROCK2PRKG1 | |
| SCHEMBL24792900 | 0.76 | PDE4B (0.39) | GPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2024-08-29 | — | — | US | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | PDE1C 2880/4885GPR119 3864/4885HDAC4 146/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | PDE1C 2880/4885GPR119 3864/4885HDAC4 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.